// App-Quantinova.ai

814 : The Chromosome 21 Kinase DYRK1A Controls Cell Cycle Exit and Survival During Lymphoid Development and Is a Novel Therapeutic Target In Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Benjamin J Thompson

Principal Investigators

  • Lauren Diebold

  • Sebastien Malinge

  • Bertrand Leblond

  • Anne-Sophie Casagrande

  • Laurent Desire

  • Alicia Foucourt

  • Thierry Besson

  • Nobuko Hijiya

  • John D. Crispino

Medical Centers

  • Institut Gustave-Roussy, Villejuif, France

  • Rouen University Hospital, Rouen, France

  • Ann & Robert H. Lurie Children's Hosp. of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL.

  • Northwestern University, Chicago, IL

  • Division of Hematology/Oncology, Northwestern University, Chicago, IL

  • Therapeutic Division, Diaxonhit Therapeutics, Paris, France

Locations

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Down syndrome

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • Cyclin dependent kinase 1

Drug/Treatment

  • Cytarabine liposomal

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved